[Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity].
Developments in the knowledge of molecular biology of cancer over the past 20 years have been identified. Angiogenesis is playing a key role in the physiopathology of cancer evolution. Several strategies have been developed to target angiogenesis for the treatment of metastatic RCC. These include inhibition of VEGF receptors (inhibition of the tyrosine kinase activity) or binding to the VEGF protein. Several additional kinases inhibitions including PDGF receptors are also targeted. Anti-angiogenic drugs recently marketed or still under clinical development, may interact with the kidneys. Clinical and pathological, and mechanisms of their renal toxicity are presented in this article.
Izzedine
Hassan
H
Service de Néphrologie, Hôpital Pitié-Salpêtrière, 83, Boulevard de l'Hôpital, 75013 Paris, France. hassan.izzedine@psl.aphp.fr
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000628:therapy; D007668:Kidney / Q000187:drug effects*; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D011507:Proteinuria / Q000139:chemically induced* / Q000628:therapy; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D042442:Vascular Endothelial Growth Factors / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042442:Vascular Endothelial Growth Factors; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor